WOODSIDE, Calif. and LAUSANNE, Switzerland, June 21, 2022 /PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as Belgian biotech company, Galapagos NV (Euronext &NASDAQ: GLPG), announced1 that it will acquire Dutch cell therapy company CellPoint. +ND Capital was the sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care.
Read more at prnewswire.com+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
